Advertisement
UK markets close in 5 hours 28 minutes
  • FTSE 100

    8,092.62
    +52.24 (+0.65%)
     
  • FTSE 250

    19,726.26
    +6.89 (+0.03%)
     
  • AIM

    755.22
    +0.53 (+0.07%)
     
  • GBP/EUR

    1.1664
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2513
    +0.0051 (+0.41%)
     
  • Bitcoin GBP

    51,111.94
    -1,928.79 (-3.64%)
     
  • CMC Crypto 200

    1,360.96
    -21.61 (-1.56%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.69
    -0.12 (-0.14%)
     
  • GOLD FUTURES

    2,338.30
    -0.10 (-0.00%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,992.74
    -95.96 (-0.53%)
     
  • CAC 40

    8,048.68
    -43.18 (-0.53%)
     

Dupixent May Be Strong Growth Driver for Sanofi in the Future

Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).